BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• 

  Business

  Viela Bio Spins Out of AstraZeneca’s MedImmune with $250 Million Series A Funding

  Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.

  February 28, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Career Advice

  The Power of Body Language in the Job Interview

  It’s not what you say sometimes but what you do. What are your non-verbal cues saying to a potential employer? Learn what to do to present yourself as the best candidate for the job, without ever saying a word.

  February 28, 2018

   · 

  6 min read

   · 

  Briana Casali
• 

  Deals

  Should Biogen Buy Alkermes?

  After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.

  February 28, 2018

   · 

  3 min read

   · 

  Karl Thiel
• 

  Bio NC

  Life Science Community Comes Together to Support Rare Disease Day

  Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.

  February 28, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Galera Therapeutics Doses First Patient in Pancreatic Cancer Trial

  Galera Therapeutics has initiated its Phase I/II clinical trial of GC4419 in locally advanced pancreatic cancer (LAPC).

  February 28, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  PharmaCyte Presents Options for Phase II Pancreatic Cancer Trial

  PharmaCyte Biotech recently discussed its options and plans for a Phase IIb clinical trial of its Cell-in-a-Box technology in pancreatic cancer.

  February 28, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Job Trends

  Inscripta Snags $55.5 Million in Funding, Looks to Expand Employment

  Gene-editing company Inscripta, formerly known as Muse Biotechnologies, will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5 million.

  February 28, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Stuns Celgene With Refusal to File Letter for MS Treatment Ozanimod

  The U.S. Food and Drug Administration stunned the company with a Refusal to File letter regarding its New Drug Application (NDA) for multiple sclerosis treatment ozanimod.

  February 28, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Reata Pharmaceuticals Updates Data Release Dates for Ongoing Phase II Trials

  Reata Pharmaceuticals has updated the timing of coming data announcements for two ongoing mid-stage trials for rare renal diseases.

  February 28, 2018

   · 

  2 min read

   · 

  Alex Keown
• BioMidwest

  American Lung Association’s Inaugural LUNG FORCE ‘State of Lung Cancer’ Report Finds Every State Must Do More to Combat Lung Cancer

  First-of-its-kind report from American Lung Association shows the impact of lung cancer and how survival rates vary state by state, as well as opportunities to save lives.

  February 28, 2018

   · 

  6 min read